A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets?

Drug Discov Today. 2020 Dec;25(12):2317-2325. doi: 10.1016/j.drudis.2020.09.038. Epub 2020 Oct 6.


Sepsis is a life-threatening condition caused by the response of the body to an infection, and has recently been regarded as a global health priority because of the lack of effective treatments available. Vascular endothelial cells have a crucial role in sepsis and are believed to be a major target of pathogens during the early stages of infection. Accumulating evidence suggests that common sepsis pathogens, including bacteria, fungi, and viruses, all contain a critical integrin recognition motif, Arg-Gly-Asp (RGD), in their major cell wall-exposed proteins that might act as ligands to crosslink to vascular endothelial cells, triggering systemic dysregulation resulting in sepsis. In this review, we discuss the potential of anti-integrin therapy in the treatment of sepsis and septic shock.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Bacterial Infections / drug therapy*
  • Humans
  • Integrins / antagonists & inhibitors*
  • Mycoses / drug therapy*
  • Oligopeptides / antagonists & inhibitors*
  • Sepsis / drug therapy*
  • Virus Diseases / drug therapy*


  • Integrins
  • Oligopeptides
  • arginyl-glycyl-aspartic acid